Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Kimball AB, et al. Among authors: prens e. Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101-6. Online ahead of print. Lancet. 2024. PMID: 38795716
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial.
Alavi A, Prens E, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, Gao H, Ranganathan U, Ivanoff NB, Hernandez Daly AC, Zouboulis CC. Alavi A, et al. Among authors: prens e. Br J Dermatol. 2024 Apr 5:ljae144. doi: 10.1093/bjd/ljae144. Online ahead of print. Br J Dermatol. 2024. PMID: 38576350
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: prens ep. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e496-e499. doi: 10.1111/jdv.19681. Epub 2023 Dec 6. J Eur Acad Dermatol Venereol. 2024. PMID: 38058224 Clinical Trial. No abstract available.
Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic-Pharmacodynamic Modeling.
van Huizen A, Bank P, van der Kraaij G, Musters A, Busard C, Menting S, Rispens T, de Vries A, van Doorn M, Prens E, Lambert J, van den Reek J, de Jong E, Mathôt R, Spuls P. van Huizen A, et al. Among authors: prens e. J Invest Dermatol. 2024 Apr;144(4):794-801.e6. doi: 10.1016/j.jid.2023.10.022. Epub 2023 Nov 20. J Invest Dermatol. 2024. PMID: 37992959 Free article.
Global consensus process to establish a core dataset for hidradenitis suppurativa registries.
Wainman HE, Chandran NS, Frew JW, Garg A, Gibbons A, Gierbolini A, Horvath B, Jemec GB, Kirby B, Kirby J, Lowes MA, Martorell A, McGrath BM, Naik HB, Oon HH, Prens E, Sayed CJ, Thorlacius L, Van der Zee HH, Villumsen B, Ingram JR. Wainman HE, et al. Among authors: prens e. Br J Dermatol. 2024 Mar 15;190(4):510-518. doi: 10.1093/bjd/ljad454. Br J Dermatol. 2024. PMID: 37976235
255 results